Resource Summary Report

Generated by RRID on Aug 7, 2026

CD279 (PD1) Antibody, anti-human, PE

RRID:AB_2727929
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-117-384, RRID:AB_2727929

Antibody Information

URL: http://antibodyregistry.org/AB_2727929

Proper Citation: Miltenyi Biotec Cat# 130-117-384, RRID:AB_2727929

Target Antigen: CD279 (PD1)

Host Organism: mouse

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-096-164. (RRID:AB_10828693).

Antibody Name: CD279 (PD1) Antibody, anti-human, PE

Description: This monoclonal targets CD279 (PD1)

Target Organism: human

Clone ID: clone PD1.3.1.3

Antibody ID: AB_2727929

Vendor: Miltenyi Biotec

Catalog Number: 130-117-384

Record Creation Time: 20250820T012335+0000

Record Last Update: 20250820T104850+0000

Ratings and Alerts

No rating or validation information has been found for CD279 (PD1) Antibody, anti-human, PE.

No alerts have been found for CD279 (PD1) Antibody, anti-human, PE.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Ciancaglini C, et al. (2026) Protocol to isolate, expand, and activate human type 2 innate lymphoid cells to study immune checkpoint function. STAR protocols, 7(2), 104461.

Marsile-Medun S, et al. (2026) Comprehensive analysis of neutrophil immunomodulatory properties and FcR dynamics in HIV-1 infection and therapy. iScience, 29(4), 115431.

Zheng X, et al. (2025) Protocol for spatial proteomic profiling of tonsil cancer microenvironments using multiplexed imaging-powered deep visual proteomics. STAR protocols, 6(3), 103901.

Miao D, et al. (2025) Photothermal nanofiber-mediated photoporation for gentle and efficient intracellular delivery of macromolecules. Nature protocols, 20(7), 1810.

Zheng X, et al. (2025) Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics. Molecular cell, 85(5), 1008.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. Cell reports. Medicine, 6(10), 102400.

Jeger-Madiot R, et al. (2022) Naive and memory CD4+ T??cell subsets can contribute to the generation of human Tfh cells. iScience, 25(1), 103566.

Wallstabe L, et al. (2019) ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI insight, 4(18).